Small but powerful: Short peptide hormones and their role in autoimmune inflammation

Journal of Neuroimmunology

Volumn 217, Issue 1-2, 2009, Pages 1-7

  Luhder F ^a   Lee, D H ^b   Gold, R ^b   Stegbauer, J ^c   Linker, R A ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bradykinin; Multiple sclerosis; Renin angiotensin system; Vascular inflammation

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ[DEXTRO PHENYLALANINE][9 DEARGININE]; CAPTOPRIL; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE RECEPTOR STIMULATING AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; LOSARTAN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y; PEPTIDE HORMONE; RENIN INHIBITOR; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1 STIMULATING AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; HORMONE ACTION; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; KIDNEY DISEASE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STROKE; T LYMPHOCYTE; TH2 CELL; UVEITIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CELL DIFFERENTIATION; DEMYELINATING AUTOIMMUNE DISEASES, CNS; HUMANS; LYMPHOCYTES; PEPTIDE HORMONES; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 70449672389     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.08.008     Document Type: Review

References (93)

1. Asashima T., Iizasa H., Terasaki T., and Nakashima E. Rat brain pericyte cell lines expressing beta2-adrenergic receptor, angiotensin II receptor type 1A, klotho, and CXCR4 mRNAs despite having endothelial cell markers. J. Cell. Physiol. 197 (2003) 69-76
2. Austinat M., Braeuninger S., Pesquero J.B., Brede M., Bader M., Stoll G., Renne T., and Kleinschnitz C. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 40 (2009) 285-293
3. Bedoui S., Miyake S., Lin Y.W., Miyamoto K., Oki S., Kawamura N., Beck-Sickinger A., von Horsten S., and Yamamura T. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J. Immunol. 171 (2003) 3451-3458
4. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman T.M., and Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 119 (2009) 524-530
5. Benter I.F., Yousif M.H., Dhaunsi G.S., Kaur J., Chappell M.C., and Diz D.I. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 28 (2008) 25-33
6. Bettelli E., Carrier Y.J., Gao W.D., Korn T., Strom T.B., Oukka M., Weiner H.L., and Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector T(H)17 and regulatory T cells. Nature 441 (2006) 235-238
7. Brenner B.M., Cooper M.E., de Z.D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (2001) 861-869
8. Burson J.M., Aguilera G., Gross K.W., and Sigmund C.D. Differential expression of angiotensin receptor 1A and 1B in mouse. Am. J. Physiol. 267 (1994) E260-E267
9. Chen M.F., Li Y.J., Yang T.L., Lou B., and Xie X.M. Losartan inhibits monocytic adhesion induced by ADMA via downregulation of chemokine receptors in monocytes. Eur. J. Clin. Pharmacol. 65 (2009) 457-465
10. Colwell C.S., Michel S., Itri J., Rodriguez W., Tam J., Lelievre V., Hu Z., Liu X., and Waschek J.A. Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am. J. Physiol. 285 (2003) R939-R949
11. Combadiere C., Potteaux S., Rodero M., Simon T., Pezard A., Esposito B., Merval R., Proudfoot A., Tedgui A., and Mallat Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117 (2008) 1649-1657
12. Constantinescu C.S., Ventura E., Hilliard B., and Rostami A. Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. Immunopharmacol. Immunotoxicol. 17 (1995) 471-491
13. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Oliveira-dos-Santos A.J., da C.J., Zhang L., Pei Y., Scholey J., Ferrario C.M., Manoukian A.S., Chappell M.C., Backx P.H., Yagil Y., and Penninger J.M. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002) 822-828
14. Crowley S.D., Vasievich M.P., Ruiz P., Gould S.K., Parsons K.K., Pazmino A.K., Facemire C., Chen B.J., Kim H.S., Tran T.T., Pisetsky D.S., Barisoni L., Prieto-Carrasquero M.C., Jeansson M., Foster M.H., and Coffman T.M. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J. Clin. Invest. 119 (2009) 943-953
15. Dai Q., Xu M., Yao M., and Sun B. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br. J. Pharmacol. 152 (2007) 1042-1048
16. De C.C., Amiri F., Brassard P., Endemann D.H., Touyz R.M., and Schiffrin E.L. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2106-2113
17. DiBona G.F., and Kopp U.C. Neural control of renal function. Physiol. Rev. 77 (1997) 75-197
18. Doerries C., Grote K., Hilfiker-Kleiner D., Luchtefeld M., Schaefer A., Holland S.M., Sorrentino S., Manes C., Schieffer B., Drexler H., and Landmesser U. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ. Res. 100 (2007) 894-903
19. Dos Santos A.C., Roffe E., Arantes R.M.E., Juliano L., Pesquero J.L., Pesquero J.B., Bader M., Teixeira M.M., and Carvalho-Tavares J. Kinin B-2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. J. Neuroinflammation 5 (2008) 49
20. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., Kintscher U., Rudolph B., Hoebeke J., Eckert D., Mazak I., Plehm R., Schonemann C., Unger T., Budde K., Neumayer H.H., Luft F.C., and Wallukat G. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352 (2005) 558-569
21. Felix D., and Schlegel W. Angiotensin receptive neurones in the subfornical organ. Structure-activity relations. Brain Res. 149 (1978) 107-116
22. Fernandez-Martin A., Gonzalez-Rey E., Chorny A., Ganea D., and Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 36 (2006) 318-326
23. Ferreira A.J., and Santos R.A. Cardiovascular actions of angiotensin-(1-7). Braz. J. Med. Biol. Res. 38 (2005) 499-507
24. Fitzsimons J.T. Angiotensin, thirst, and sodium appetite. Physiol. Rev. 78 (1998) 583-686
25. Fleegal-DeMotta M.A., Doghu S., and Banks W.A. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J. Cereb. Blood Flow Metab. 29 (2009) 640-647
26. Germain L., Barabe J., and Galeano C. Increased blood-concentration of Des-Arg9-bradykinin in experimental allergic encephalomyelitis. J. Neurol. Sci. 83 (1988) 211-217
27. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006) 1953-1971
28. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Martin J., Pozo D., Ganea D., and Delgado M. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis - down-regulation of inflammatory and autoimmune responses. Am. J. Pathol. 168 (2006) 1179-1188
29. Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D.E., and Spier A.D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP - a view of neuroprotection and cell division. J. Mol. Neurosci. 20 (2003) 315-322
30. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74 (1994) 1141-1148
31. Griendling K.K., Lassegue B., and Alexander R.W. Angiotensin receptors and their therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 281-306
32. Grimm M.C., Newman R., Hassim Z., Cuan N., Connor S.J., Le Y.Y., Wang J.M., Oppenheim J.J., and Lloyd A.R. Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J. Immunol. 171 (2003) 4990-4994
33. Grote K., Ortmann M., Salguero G., Doerries C., Landmesser U., Luchtefeld M., Brandes R.P., Gwinner W., Tschernig T., Brabant E.G., Klos A., Schaefer A., Drexler H., and Schieffer B. Critical role for p47phox in renin-angiotensin system activation and blood pressure regulation. Cardiovasc. Res. 71 (2006) 596-605
34. Gurley S.B., and Coffman T.M. Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. Exp. Physiol. 93 (2008) 538-542
35. Gurley S.B., Allred A., Le T.H., Griffiths R., Mao L., Philip N., Haystead T.A., Donoghue M., Breitbart R.E., Acton S.L., Rockman H.A., and Coffman T.M. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Invest. 116 (2006) 2218-2225
36. Guyton A.C. Blood pressure control - special role of the kidneys and body fluids. Science 252 (1991) 1813-1816
37. Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., Goronzy J., Weyand C., and Harrison D.G. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204 (2007) 2449-2460
38. Hassani H., Lucas G., Rozell B., and Ernfors P. Attenuation of acute experimental colitis by preventing NPYY1 receptor signaling. Am. J. Physiol. 288 (2005) G550-G556
39. Henke N., Schmidt-Ullrich R., Dechend R., Park J.K., Qadri F., Wellner M., Obst M., Gross V., Dietz R., Luft F.C., Scheidereit C., and Muller D.N. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ. Res. 101 (2007) 268-276
40. Hoch N.E., Guzik T.J., Chen W., Deans T., Maalouf S.A., Gratze P., Weyand C., and Harrison D.G. Regulation of T-cell function by endogenously produced angiotensin II. Am. J. Physiol. 296 (2009) R208-R216
41. Ishibashi M., Hiasa K., Zhao Q., Inoue S., Ohtani K., Kitamoto S., Tsuchihashi M., Sugaya T., Charo I.F., Kura S., Tsuzuki T., Ishibashi T., Takeshita A., and Egashira K. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ. Res. 94 (2004) 1203-1210
42. Izikson L., Klein R.S., Charo I.F., Weiner H.L., and Luster A.D. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192 (2000) 1075-1080
43. Kaschina E., Grzesiak A., Li J., Foryst-Ludwig A., Timm M., Rompe F., Sommerfeld M., Kemnitz U.R., Curato C., Namsolleck P., Tschope C., Hallberg A., Alterman M., Hucko T., Paetsch I., Dietrich T., Schnackenburg B., Graf K., Dahlof B., Kintscher U., Unger T., and Steckelings U.M. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?. Circulation 118 (2008) 2523-2532
44. Kato H., Ito A., Kawanokuchi J., Jin S.J., Mizuno T., Ojika K., Ueda R., and Suzumura A. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult. Scler. 10 (2004) 651-659
45. Kawano S., Kubota T., Monden Y., Kawamura N., Tsutsui H., Takeshita A., and Sunagawa K. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc. Res. 67 (2005) 689-698
46. Kvakan H., Kleinewietfeld M., Qadri F., Park J.K., Fischer R., Schwarz I., Rahn H.P., Plehm R., Wellner M., Elitok S., Gratze P., Dechend R., Luft F.C., and Muller D.N. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 119 (2009) 2904-2912
47. Lemos V.S., Silva D.M., Walther T., Alenina N., Bader M., and Santos R.A. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J. Cardiovasc. Pharmacol. 46 (2005) 274-279
48. Linker R., Gold R., and Lühder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev. Immunol. 29 (2009) 43-68
49. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., and van Gilst W.H. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105 (2002) 1548-1550
50. Lovren F., Pan Y., Quan A., Teoh H., Wang G., Shukla P.C., Levitt K.S., Oudit G.Y., Al-Omran M., Stewart D.J., Slutsky A.S., Peterson M.D., Backx P.H., Penninger J.M., and Verma S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. 295 (2008) H1377-H1384
51. Luft F.C., and Weinberger M.H. Antihypertensive therapy with aliskiren. Kidney Int. 73 (2008) 679-683
52. Mapp P.I., Kidd B.L., Gibson S.J., Terry J.M., Revell P.A., Ibrahim N.B.N., Blake D.R., and Polak J.M. Substance-P-related, calcitonin gene-related peptide-flanking and C-flanking peptide of neuropeptide-Y-immunoreactive fibers are present in normal synovium but depleted in patients with rheumatoid-arthritis. Neuroscience 37 (1990) 143-153
53. Marchesi C., Paradis P., and Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 29 (2008) 367-374
54. Masaki H., Kurihara T., Yamaki A., Inomata N., Nozawa Y., Mori Y., Murasawa S., Kizima K., Maruyama K., Horiuchi M., Dzau V.J., Takahashi H., Iwasaka T., Inada M., and Matsubara H. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J. Clin. Invest. 101 (1998) 527-535
55. Mehta P.K., and Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. 292 (2007) C82-C97
56. Mukoyama M., Nakajima M., Horiuchi M., Sasamura H., Pratt R.E., and Dzau V.J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 268 (1993) 24539-24542
57. Müller D.N., Shagdarsuren E., Park J.K., Dechend R., Mervaala E., Hampich F., Fiebeler A., Ju X., Finckenberg P., Theuer J., Viedt C., Kreuzer J., Heidecke H., Haller H., Zenke M., and Luft F.C. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am. J. Pathol. 161 (2002) 1679-1693
58. Murphy T.J., Alexander R.W., Griendling K.K., Runge M.S., and Bernstein K.E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351 (1991) 233-236
59. Nahmod K.A., Vermeulen M.E., Raiden S., Salamone G., Gamberale R., Fernandez-Calotti P., Alvarez A., Nahmod V., Giordano M., and Geffner J.R. Control of dendritic cell differentiation by angiotensin II. FASEB J. 17 (2003) 491-493
60. Nessler S., Stadelmann C., Bittner A., Schlegel K., Gronen F., Brück W., Hemmer B., and Sommer N. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist - a putative role for substance P in CNS inflammation. J. Neuroimmunol. 179 (2006) 1-8
61. Oudit G.Y., Kassiri Z., Patel M.P., Chappell M., Butany J., Backx P.H., Tsushima R.G., Scholey J.W., Khokha R., and Penninger J.M. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 75 (2007) 29-39
62. Pan H.L. Brain angiotensin II and synaptic transmission. Neuroscientist 10 (2004) 422-431
63. Park J.K., Fischer R., Dechend R., Shagdarsuren E., Gapeljuk A., Wellner M., Meiners S., Gratze P., Al-Saadi N., Feldt S., Fiebeler A., Madwed J.B., Schirdewan A., Haller H., Luft F.C., and Muller D.N. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension 49 (2007) 481-489
64. Paul M., Poyan M.A., and Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 86 (2006) 747-803
65. Pavel J., Tang H., Brimijoin S., Moughamian A., Nishioku T., Benicky J., and Saavedra J.M. Expression and transport of angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat. Brain Res. 1246 (2008) 111-122
66. Peach M.J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev. 57 (1977) 313-370
67. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., Funk G.C., Hamilton G., Novotny C., Burian B., and Block L.H. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111 (2003) 1339-1346
68. Phillips M.I., and de Oliveira E.M. Brain renin angiotensin in disease. J. Mol. Med. 86 (2008) 715-722
69. Piper P.J., Said S.I., and Vane J.R. Effects on smooth muscle preparations of unidentified vasoactive peptides from intestine and lung. Nature 225 (1970) 1144-&
70. Platten M., Youssef S., Hur E.M., Ho M., Han M., Lanz T., Phillips L., Goldstein M., Bhat R., Raine C.S., Sobel R.A., and Steinman L. Blocking angiotensin converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 14948-14953
71. Pozo D., and Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. FASEB J. 18 (2004) 1325-1334
72. Prat A., Biernacki K., Saroli T., Orav J.E., Guttmann C.R.G., Weiner H.L., Khoury S.J., and Antel J.P. Kinin B-1 receptor expression on multiple sclerosis mononuclear cells - correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch. Neurol. 62 (2005) 795-800
73. Prod'homme T., Weber M.S., Steinman L., and Zamvil S.S. A neuropeptide in immune-mediated inflammation, Y?. Trends Immunol. 27 (2006) 164-167
74. Reichardt H.M., and Lühder F. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit. Rev. Immunol. 29 (2009) 255-273
75. Said S.I., and Mutt V. Polypeptide with broad biological activity - isolation from small intestine. Science 169 (1970) 1217-1218
76. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de B.I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., and Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8258-8263
77. Schieffer B., Luchtefeld M., Braun S., Hilfiker A., Hilfiker-Kleiner D., and Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ. Res. 87 (2000) 1195-1201
78. Schmeisser A., Soehnlein O., Illmer T., Lorenz H.M., Eskafi S., Roerick O., Gabler C., Strasser R., Daniel W.G., and Garlichs C.D. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem. Biophys. Res. Commun. 325 (2004) 532-540
79. Schulze-Topphoff U., Prat A., Prozorovski T., Siffrin V., Paterka M., Herz J., Bendix I., Ifergan I., Schadock I., Mori M.A., Van H.J., Schroter F., Smorodchenko A., Han M.H., Bader M., Steinman L., Aktas O., and Zipp F. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat. Med. 15 (2009) 788-793
80. Shanmugam S., and Sandberg K. Ontogeny of angiotensin II receptors. Cell Biol. Int. 20 (1996) 169-176
81. Soehnlein O., Schmeisser A., Cicha I., Reiss C., Ulbrich H., Lindbom L., Daniel W.G., and Garlichs C.D. ACE inhibition lowers angiotensin-II-induced monocyte adhesion to HUVEC by reduction of p65 translocation and AT 1 expression. J. Vasc. Res. 42 (2005) 399-407
82. Stegbauer J., Vonend O., Oberhauser V., and Rump L.C. Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney. J. Hypertens. 21 (2003) 1391-1399
83. Stegbauer J., Oberhauser V., Vonend O., and Rump L.C. Angiotensin-(1-7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats. Cardiovasc. Res. 61 (2004) 352-359
84. Stegbauer J., Lee D., Seubert S., Ellrichmann G., Manzel A., Kvakan H., Muller D.N., Gaupp S., Rump L., Gold R., and Linker R.A. Role of the renin angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 14942-14947
85. Tan Y.V., Abad C., Lopez R., Dong H.M., Liu S., Lee A., Gomariz R.P., Leceta J., and Waschek J.A. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci U. S. A 106 (2009) 2012-2017
86. Tharaux P.L., and Coffman T.M. Transgenic mice as a tool to study the renin-angiotensin system. Contrib. Nephrol. (2001) 72-91
87. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., and Smith R.D. New perspectives in angiotensin system control. J. Hum. Hypertens. 7 Suppl 2 (1993) S19-S31
88. Towler P., Staker B., Prasad S.G., Menon S., Tang J., Parsons T., Ryan D., Fisher M., Williams D., Dales N.A., Patane M.A., and Pantoliano M.W. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 279 (2004) 17996-18007
89. Wolf G., Schneider A., Helmchen U., and Stahl R.A. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp. Nephrol. 6 (1998) 112-120
90. Wosik K., Cayrol R., Dodelet-Devillers A., Berthelet F., Bernard M., Moumdjian R., Bouthillier A., Reudelhuber T.L., and Prat A. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J. Neurosci. 27 (2007) 9032-9042
91. Wu K., Zhou T., Sun G., Wang W., Zhang Y., Zhang Y., Hao L., and Chen N. Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue. Cell. Mol. Immunol. 3 (2006) 213-220
92. Xie Q.Y., Sun M., Yang T.L., and Sun Z.L. Losartan reduces monocyte chemoattractant protein-1 expression in aortic tissues of 2K1C hypertensive rats. Int. J. Cardiol. 110 (2006) 60-66
93. Xu H.X., Li J.J., Li G.S., Wang J., Li N.X., and Peng J. Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. Acta Cardiol. 62 (2007) 607-613